rs113993959
From SNPedia
| Cystic Fibrosis related |
| Orientation | plus |
| Stabilized | plus |
| Geno | Mag | Summary |
|---|---|---|
| (G;G) | 0 | normal |
| (G;T) | 3 | carrier for G542X cystic fibrosis mutation |
| (T;T) | 4 | Cystic Fibrosis; homozygote for G542X mutation |
| Reference | GRCh38 38.1/141 |
| Chromosome | 7 |
| Position | 117587778 |
| Gene | CFTR |
| is a | snp |
| is | mentioned by |
| dbSNP | rs113993959 |
| dbSNP (classic) | rs113993959 |
| ClinGen | rs113993959 |
| ebi | rs113993959 |
| HLI | rs113993959 |
| Exac | rs113993959 |
| Gnomad | rs113993959 |
| Varsome | rs113993959 |
| LitVar | rs113993959 |
| Map | rs113993959 |
| PheGenI | rs113993959 |
| Biobank | rs113993959 |
| 1000 genomes | rs113993959 |
| hgdp | rs113993959 |
| ensembl | rs113993959 |
| geneview | rs113993959 |
| scholar | rs113993959 |
| rs113993959 | |
| pharmgkb | rs113993959 |
| gwascentral | rs113993959 |
| openSNP | rs113993959 |
| 23andMe | rs113993959 |
| SNPshot | rs113993959 |
| SNPdbe | rs113993959 |
| MSV3d | rs113993959 |
| GWAS Ctlg | rs113993959 |
| Max Magnitude | 4 |
rs113993959, also known as c.1624G>T, Gly542Ter or G542X, is a SNP in the CFTR cystic fibrosis gene. This mutation is fairly rare, but in Ashkenazi Jews it accounts for ~13% of all cases of cystic fibrosis. See also OMIM 602421.0009.
In 23andMe, rs113993959 may be called one of several names: i4000300, i5006109 or i5011314.
| ClinVar | |
|---|---|
| Risk | Rs113993959(T;T) |
| Alt | Rs113993959(T;T) |
| Reference | Rs113993959(G;G) |
| Significance | Drug-response |
| Disease | Cystic fibrosis not provided Hereditary pancreatitis ataluren response - Efficacy |
| Variation | info |
| Gene | CFTR |
| CLNDBN | Cystic fibrosis not provided Hereditary pancreatitis ataluren response - Efficacy |
| Reversed | 0 |
| HGVS | NC_000007.13:g.117227832G>T |
| CLNSRC | HGMD OMIM Allelic Variant |
| CLNACC | RCV000007535.11, RCV000058931.5, RCV000119041.3, RCV000417172.1, |
[PMID 15948195] Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening.
